Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study is to assess the safety and tolerability of a five-day titration schedule (using
twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg
daily. The study duration is two months.
Phase:
Phase 2
Details
Lead Sponsor:
Solvay Pharmaceuticals
Collaborators:
H. Lundbeck A/S Wyeth is now a wholly owned subsidiary of Pfizer